Lineage Cell Therapeutics Inc (LCTX)

[Cincinnatus]

Nowhere does it say anything about a topical application for the heart.
Topical is mentioned, yes, but you are ignoring the quote..."subsequently initiate three clinical trials of cell- and drug-based therapies, each targeting large unmet needs in age-related medicine.

We know that part of the Renelon process involves an already FDA approved product (but we don't know what or how many different formats that product may assume.)

With three different targets mentioned, it seems significant that after they mention congestive heart failure the next sentence begins with "In addition" and then go on to mention a topical application.

So, it seems to me Renelon has three different targets. Whether they can get the device approval for all three targets or just for the topical application is an open question... I'm hoping the preclinical results point to one of the three (topical) being the most reliable and noteworthy, and if it's a success they could go back for approval of the other two when they have good results with the topical application.

Speculation and dreaming here!!